Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse

Expert Review of Vaccines

Volumn 12, Issue 3, 2013, Pages 323-332

  Brimijoin, Stephen ^a   Shen, Xiaoyun ^b,c   Orson, Frank ^b,c   Kosten, Thomas ^b,c  

^a MAYO GRADUATE SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

adenovirus gene transfer vector; antidrug immunoglobulin; butyrylcholinesterase; clinical trial; cocaine abuse; cocaine hydrolase; metabolism based therapies; monoclonal antibody; vaccine

Indexed keywords

ADENOVIRUS VECTOR; CHOLINESTERASE; DEXAMETHASONE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NIC 9D9; NICOTINE VACCINE; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; BLINDNESS; BLOOD CLOTTING DISORDER; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; COCH GENE; DRUG DEPENDENCE TREATMENT; DRUG MEGADOSE; DRUG METABOLISM; GENE TRANSFER; GENETIC TRANSDUCTION; HEROIN DEPENDENCE; HUMAN; IMMUNE DEFICIENCY; METHAMPHETAMINE DEPENDENCE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; TOBACCO DEPENDENCE; TRANSGENE; VACCINATION;

ANTIBODIES, MONOCLONAL; COCAINE; COCAINE-RELATED DISORDERS; GENE TRANSFER TECHNIQUES; HUMANS; HYDROLASES; VACCINES;

EID: 84875130963     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.1     Document Type: Review

References (94)

1. Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. Clin. Pharmacol. Ther. 91(1), 60-70 (2012).
2. Shen X, Kosten TR. Immunotherapy for drug abuse. CNS Neurol. Disord. Drug Targets 10(8), 876-879 (2011).
3. Shen X, Orson FM, Kosten TR. Antiaddiction vaccines. F1000 Med. Rep. 3, 20 (2011).
4. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR. Substance abuse vaccines. Ann. N. Y. Acad. Sci. 1141, 257-269 (2008).
5. Hatsukami DK, Stead LF, Gupta PC. Tobacco addiction. Lancet 371(9629), 2027-2038 (2008).
6. LeSage MG, Keyler DE, Pentel PR. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J. 8(1), E65-E75 (2006).
7. Gentry WB, Rüedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Hum. Vaccin. 5(4), 206-213 (2009).
8. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry 58(2), 158-164 (2005).
9. Hamaoka T, Takatsu K, Kitagawa M. Antibody production in mice. V. The suppressive effect of anti-carrier antibodies on cellular cooperation in the induction of secondary anti-hapten antibody responses. Immunology 24(3), 409-424 (1973).
10. Hicks MJ, De BP, Rosenberg JB et al. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol. Ther. 19(3), 612-619 (2011).
11. Fox BS, Kantak KM, Edwards MA et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. 2(10), 1129-1132 (1996).
12. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252(5485), 708-710 (1974).
13. Peterson EC, Gunnell M, Che Y et al. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J. Pharmacol. Exp. Ther. 322(1), 30-39 (2007).
14. McMillan DE, Hardwick WC, Li M et al. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J. Pharmacol. Exp. Ther. 309(3), 1248-1255 (2004).
15. Roiko SA, Harris AC, LeSage MG, Keyler DE, Pentel PR. Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats. Pharmacol. Biochem. Behav. 93(2), 105-111 (2009).
16. Keyler D, Pentel PR, Kuehl G, Collins G, Murphy SE. Effects of nicotine infusion on the metabolism of the tobacco carcinogen 4-(methylnitrosamino)-1-(3- pyridyl)-1- butanone (NNK) in rats. Cancer Lett. 202(1), 1-9 (2003).
17. Norman AB, Tabet MR, Norman MK, Buesing WR, Pesce AJ, Ball WJ. A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J. Pharmacol. Exp. Ther. 320(1), 145-153 (2007).
18. Hieda Y, Keyler DE, Vandevoort JT et al. Active immunization alters the plasma nicotine concentration in rats. J. Pharmacol. Exp. Ther. 283(3), 1076-1081 (1997).
19. Byrnes-Blake KA, Laurenzana EM, Carroll FI et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur. J. Pharmacol. 461(2-3), 119-128 (2003).
20. Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur. J. Pharmacol. 521(1-3), 86-94 (2005).
21. Samaha AN, Li Y, Robinson TE. The rate of intravenous cocaine administration determines susceptibility to sensitization. J. Neurosci. 22(8), 3244-3250 (2002).
22. Gossop M, Griffiths P, Powis B, Strang J. Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br. J. Addict. 87(11), 1527-1536 (1992).
23. Kosten TR, Rosen M, Bond J et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20(7-8), 1196-1204 (2002).
24. Cornuz J, Zwahlen S, Jungi WF et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 3(6), e2547 (2008).
25. Hatsukami DK, Rennard S, Jorenby D et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. 78(5), 456-467 (2005).
26. Orson F, Rossen RD, Shen X, Lopez AY, Wu Y, Kosten T. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am. J. Addict. 22(2), 169-174 (2012).
27. Norman AB, Norman MK, Buesing WR, Tabet MR, Tsibulsky VL, Ball WJ. The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 328(3), 873-881 (2009).
28. Laurenzana EM, Byrnes-Blake KA, Milesi-Hallé A, Gentry WB, Williams DK, Owens SM. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab. Dispos. 31(11), 1320-1326 (2003).
29. Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80(1-2), 148-158 (2003).
30. Lozier JN, Csako G, Mondoro TH et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum. Gene Ther. 13(1), 113-124 (2002).
31. Rivat C, Santilli G, Gaspar HB, Thrasher AJ. Gene therapy for primary immunodeficiencies. Hum. Gene Ther. 23(7), 668-675 (2012).
32. Stieger K, Lorenz B. Gene therapy for vision loss - recent developments. Discov. Med. 10(54), 425-433 (2010).
33. Shashidharamurthy R, Bozeman EN, Patel J, Kaur R, Meganathan J, Selvaraj P. Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development. Med. Res. Rev. 32(6), 1197-1219 (2012).
34. Fang J, Qian JJ, Yi S et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23(5), 584-590 (2005).
35. Sanhadji K, Grave L, Touraine JL et al. Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice. AIDS 14(18), 2813-2822 (2000).
36. Hicks MJ, Rosenberg JB, De BP et al. AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci. Transl. Med. 4(140), 140ra87 (2012).
37. Russell MA, Wilson C, Patel UA, Feyerabend C, Cole PV. Plasma nicotine levels after smoking cigarettes with high, medium, and low nicotine yields. Br. Med. J. 2(5968), 414-416 (1975).
38. Rosenberg JB, Hicks MJ, De BP et al. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum. Gene Ther. 23(5), 451-459 (2012).
39. Zufferey R, Dull T, Mandel RJ et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72(12), 9873-9880 (1998).
40. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644), 415-419 (2003).
41. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 270(5235), 404-410 (1995).
42. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helperdependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl Acad. Sci. USA 93(24), 13565-13570 (1996).
43. Kaplitt MG, Leone P, Samulski RJ et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8(2), 148-154 (1994).
44. Kuntz E, Yusenko MV, Nagy A, Kovacs G. Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease. Hum. Pathol. 41(9), 1345-1349 (2010).
45. Spalding KL, Bhardwaj RD, Buchholz BA, Druid H, Frisén J. Retrospective birth dating of cells in humans. Cell 122(1), 133-143 (2005).
46. Muruve DA. The innate immune response to adenovirus vectors. Hum. Gene Ther. 15(12), 1157-1166 (2004).
47. Brunetti-Pierri N, Ng P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther. 15(8), 553-560 (2008).
48. Brunetti-Pierri N, Ng P. Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum. Mol. Genet. 20(R1), R7-13 (2011).
49. Morral N, O'Neal W, Rice K et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl Acad. Sci. USA 96(22), 12816-12821 (1999).
50. Brantly ML, Chulay JD, Wang L et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl Acad. Sci. USA 106(38), 16363-16368 (2009).
51. Manno CS, Pierce GF, Arruda VR et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12(3), 342-347 (2006).
52. Vetrini F, Ng P. Liver-directed gene therapy with helper-dependent adenoviral vectors: current state of the art and future challenges. Curr. Pharm. Des. 17(24), 2488-2499 (2011).
53. Seregin SS, Appledorn DM, McBride AJ et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol. Ther. 17(4), 685-696 (2009).
54. Kumahara K, Nagata H, Watanabe K et al. Suppression of inflammation by dexamethasone prolongs adenoviral vector-mediated transgene expression in murine nasal mucosa. Acta Otolaryngol. 125(12), 1301-1306 (2005).
55. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 15(1), 35-46 (2004).
56. Stewart DJ, Inaba T, Tang BK, Kalow W. Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci. 20(9), 1557-1563 (1977).
57. Howard LA, Sellers EM, Tyndale RF. The role of pharmacogenetically- variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 3(2), 185-199 (2002).
58. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 68(1), 35-43 (2000).
59. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend. 48(3), 159-165 (1997).
60. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, Lockridge O. An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol. Pharmacol. 55(1), 83-91 (1999).
61. Sun H, Pang YP, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol. 62(2), 220-224 (2002).
62. Sun L, Lau CE. Simultaneous pharmacokinetic modeling of cocaine and its metabolites, norcocaine and benzyoylecgonine, after intravenous and oral administration in rats. Drug Metab. Disp. 29, 1183-1189 (2001).
63. Pan Y, Gao D, Yang W et al. Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc. Natl Acad. Sci. USA 102(46), 16656-16661 (2005).
64. Yang W, Xue L, Fang L, Chen X, Zhan CG. Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem. Biol. Interact. 187(1-3), 148-152 (2010).
65. Zheng F, Yang W, Ko MC et al. Most efficient cocaine hydrolase designed by virtual screening of transition states. J. Am. Chem. Soc. 130(36), 12148-12155 (2008).
66. Brimijoin S, Gao Y, Anker JJ et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33(11), 2715-2725 (2008).
67. Anker JJ, Brimijoin S, Gao Y et al. Cocaine hydrolase encoded in viral vector blocks the reinstatement of cocaine seeking in rats for months. Biol. Psychiatry 71(8), 700-705 (2012).
68. Saxena A, Sun W, Fedorko JM, Koplovitz I, Doctor BP. Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX. Biochem. Pharmacol. 81(1), 164-169 (2011).
69. Saxena A, Sun W, Luo C, Doctor BP. Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice. Chem. Biol. Interact. 199-203 (2005).
70. Weber A, Butterweck H, Mais-Paul U et al. Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use. Vox Sang. 100(3), 285-297 (2011).
71. Gao Y, Atanasova E, Sui N, Pancook JD, Watkins JD, Brimijoin S. Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol. Pharmacol. 67(1), 204-211 (2005).
72. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc. Natl Acad. Sci. USA 92(9), 3854-3858 (1995).
73. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and ?-galactosidase. Proc. Natl Acad. Sci. USA 93(12), 5731-5736 (1996).
74. Miyagi N, Rao VP, Ricci D et al. Efficient and durable gene transfer to transplanted heart using adeno-associated virus 9 vector. J. Heart Lung Transplant. 27(5), 554-560 (2008).
75. Schirmer JM, Miyagi N, Rao VP et al. Recombinant adeno-associated virus vector for gene transfer to the transplanted rat heart. Transpl. Int. 20(6), 550-557 (2007).
76. Kim IH, Józkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl Acad. Sci. USA 98(23), 13282-13287 (2001).
77. Gao Y, Geng L, Orson F et al. Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage. Chem Biol. Interact. doi:10.1016/j. cbi.2012.08.006 (2012) (Epub ahead of print).
78. Wise RA, Kiyatkin EA. Differentiating the rapid actions of cocaine. Nat. Rev. Neurosci. 12(8), 479-484 (2011).
79. Ramakrishnan M, Alves De Melo F, Kinsey BM, Ladbury JE, Kosten TR, Orson FM. Probing cocaine-antibody interactions in buffer and human serum. PLoS ONE 7(7), e40518 (2012).
80. Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S. The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem. Biol. Interact. 187(1-3), 421-424 (2010).
81. Carroll ME, Zlebnik NE, Anker JJ et al. Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion. PLoS ONE 7(8), e43536 (2012).
82. Mastrangeli A, Harvey BG, Yao J et al. 'Sero-switch' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7(1), 79-87 (1996).
83. Gao Y, Brimijoin S. Lasting reduction of cocaine action in neostriatum-a hydrolase gene therapy approach. J. Pharmacol. Exp. Ther. 330(2), 449-457 (2009).
84. Scott EM. Inheritance of two types of deficiency of human serum cholinesterase. Ann. Hum. Genet. 37(2), 139-143 (1973).
85. Hodgkin W, Giblett ER, Levine H, Bauer W, Motulsky AG. Complete pseudocholinesterase deficiency: genetic and immunologic characterization. J. Clin. Invest. 44, 486-493 (1965).
86. Xue L, Ko MC, Tong M et al. Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol. Pharmacol. 79(2), 290-297 (2011).
87. Myers TM, Sun W, Naik RS, Clark MG, Doctor BP, Saxena A. Characterization of human serum butyrylcholinesterase in rhesus monkeys: behavioral and physiological effects. Neurotoxicol. Teratol. 34(3), 323-330 (2012).
88. Rosenberg YJ, Saxena A, Sun W et al. Demonstration of in vivo stability and lack of immunogenicity of a polyethyleneglycolconjugated recombinant CHO-derived butyrylcholinesterase bioscavenger using a homologous macaque model. Chem. Biol. Interact. 187(1-3), 279-286 (2010).
89. Genovese RF, Sun W, Johnson CC, Ditargiani RC, Doctor BP, Saxena A. Safety of administration of human butyrylcholinesterase and its conjugates with soman or VX in rats. Basic Clin. Pharmacol. Toxicol. 106(5), 428-434 (2010).
90. Li B, Stribley JA, Ticu A et al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J. Neurochem. 75(3), 1320-1331 (2000).
91. Silver A. Biology of Cholinesterases. North Holland Publishing Co., Amsterdam, The Netherlands (1974).
92. Anglister L, Eichler J, Szabo M, Haesaert B, Salpeter MM. 125I-labeled fasciculin 2: a new tool for quantitation of acetylcholinesterase densities at synaptic sites by EM-autoradiography. J. Neurosci. Methods 81(1-2), 63-71 (1998).
93. Duysen EG, Lockridge O. Whole body and tissue imaging of the butyrylcholinesterase knockout mouse injected with near infrared dye labeled butyrylcholinesterase. Chem. Biol. Interact. 175(1-3), 119-124 (2008).
94. Painter D, Tice P. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings (2010). http://oas.samhsa.gov/ NSDUH/2k10NSDUH/2k10Results.pdf